Rezolute, Inc. – NASDAQ:RZLT
Founder-led company
Rezolute stock price today
$6.28
+1.32
+26.61%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Rezolute stock price monthly change
+5.53%
month
Rezolute stock price quarterly change
+5.53%
quarter
Rezolute stock price yearly change
+416.67%
year
Rezolute key metrics
Market Cap | 251.39M |
Enterprise value | N/A |
P/E | -1.9 |
EV/Sales | N/A |
EV/EBITDA | 0.97 |
Price/Sales | N/A |
Price/Book | 0.72 |
PEG ratio | -0.11 |
EPS | -1.18 |
Revenue | N/A |
EBITDA | -55.83M |
Income | -54.88M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRezolute stock price history
Rezolute stock forecast
Rezolute financial statements
| Jun 2022 | 0 | -9.42M | |
|---|---|---|---|
| Mar 2023 | 0 | -15.68M | |
| Jun 2023 | 0 | -12.72M | |
| Mar 2024 | 0 | -17.05M |
| Oct 2025 | 0 | -23.88M | |
|---|---|---|---|
| Dec 2025 | 0 | -24.38M | |
| Mar 2026 | 0 | -25.40M | |
| Jul 2026 | 0 | -33.02M |
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 150208000 | 8.94M | 5.95% |
|---|---|---|---|
| Mar 2023 | 134205000 | 6.88M | 5.13% |
| Jun 2023 | 123721000 | 7.54M | 6.1% |
| Mar 2024 | 87737000 | 16.87M | 19.23% |
| Jun 2022 | -12.11M | 0 | 94.10M |
|---|---|---|---|
| Mar 2023 | -18.04M | -94.95M | 0 |
| Jun 2023 | -11.35M | -6.35M | 0 |
| Mar 2024 | -15.24M | 8.67M | -3K |
Rezolute alternative data
| Aug 2023 | 47 |
|---|---|
| Sep 2023 | 47 |
| Oct 2023 | 51 |
| Nov 2023 | 51 |
| Dec 2023 | 50 |
| Jan 2024 | 50 |
| Feb 2024 | 50 |
| Mar 2024 | 57 |
| Apr 2024 | 57 |
| May 2024 | 57 |
| Jun 2024 | 57 |
| Jul 2024 | 41 |
Rezolute other data
20.50%
-27.89%
of RZLT is owned by hedge funds
12
-22
10.54M
-13.91M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 66400 | 0 |
| Mar 2024 | 118003 | 0 |
| May 2024 | 3451 | 0 |
| Jun 2024 | 52415 | 0 |
| Sep 2024 | 4259 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | HOGENHUIS WLADIMIR director | Common Stock | 4,259 | $4.7 | $20,017 | ||
Purchase | HOGENHUIS WLADIMIR director | Common Stock | 4,815 | $4.15 | $19,982 | ||
Purchase | ROBERTS BRIAN KENNETH officer: Chief Me.. | Common Shares | 300 | $3.96 | $1,188 | ||
Purchase | ROBERTS BRIAN KENNETH officer: Chief Me.. | Common Shares | 4,000 | $3.91 | $15,640 | ||
Purchase | ROBERTS BRIAN KENNETH officer: Chief Me.. | Common Shares | 3,000 | $3.91 | $11,724 | ||
Purchase | ROBERTS BRIAN KENNETH officer: Chief Me.. | Common Shares | 300 | $3.97 | $1,191 | ||
Purchase | EVANS DARON officer: CFO | Common Shares | 40,000 | $4.04 | $161,560 | ||
Purchase | EVANS DARON officer: CFO | Common Shares | 451 | $3.5 | $1,579 | ||
Purchase | EVANS DARON officer: CFO | Common Shares | 2,942 | $3.23 | $9,503 | ||
Purchase | EVANS DARON officer: CFO | Common Shares | 58 | $2.85 | $165 |
| Patent |
|---|
Grant Filling date: 7 Jul 2020 Issue date: 19 Apr 2022 |
Grant Filling date: 7 Jul 2020 Issue date: 8 Mar 2022 |
Application Filling date: 7 Jul 2020 Issue date: 14 Jan 2021 |
Application Filling date: 7 Jul 2020 Issue date: 14 Jan 2021 |
Grant Utility: Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates Filling date: 11 Jul 2018 Issue date: 7 Jul 2020 |
Application Filling date: 17 Dec 2019 Issue date: 30 Apr 2020 |
Grant Utility: Coiled tube emulsification systems Filling date: 15 Sep 2017 Issue date: 18 Feb 2020 |
-
What's the price of Rezolute stock today?
One share of Rezolute stock can currently be purchased for approximately $6.28.
-
When is Rezolute's next earnings date?
Unfortunately, Rezolute's (RZLT) next earnings date is currently unknown.
-
Does Rezolute pay dividends?
No, Rezolute does not pay dividends.
-
How much money does Rezolute make?
Rezolute has a market capitalization of 251.39M.
-
What is Rezolute's stock symbol?
Rezolute, Inc. is traded on the NASDAQ under the ticker symbol "RZLT".
-
What is Rezolute's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Rezolute?
Shares of Rezolute can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Rezolute's key executives?
Rezolute's management team includes the following people:
- Mr. Nevan Charles Elam Founder, Chief Executive Officer & Director(age: 58, pay: $1,010,000)
- Dr. Brian Kenneth Roberts M.D. Senior Vice President & Head of Clinical Devel.(age: 50, pay: $744,740)
-
Is Rezolute founder-led company?
Yes, Rezolute is a company led by its founder Mr. Nevan Charles Elam.
-
How many employees does Rezolute have?
As Jul 2024, Rezolute employs 41 workers, which is 28% less then previous month and 28% less then previous quarter.
-
When Rezolute went public?
Rezolute, Inc. is publicly traded company for more then 12 years since IPO on 14 Jan 2013.
-
What is Rezolute's official website?
The official website for Rezolute is rezolutebio.com.
-
Where are Rezolute's headquarters?
Rezolute is headquartered at 201 Redwood Shores Parkway, Redwood City, CA.
-
How can i contact Rezolute?
Rezolute's mailing address is 201 Redwood Shores Parkway, Redwood City, CA and company can be reached via phone at +65 02064507.
Rezolute company profile:
Rezolute, Inc.
rezolutebio.comExchange:
NASDAQ
Full time employees:
59
Industry:
Biotechnology
Sector:
Healthcare
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
201 Redwood Shores Parkway
Redwood City, CA 94065
Redwood City, CA 94065
CIK: 0001509261
ISIN: US76200L3096
CUSIP: 76200L309
